High intrapatient variability of tacrolimus exposure associated with poorer outcomes in liver transplantation.

ABSTRACT: Tacrolimus (TAC) is a dose-dependent immunosuppressor with considerable intrapatient variability (IPV) in its pharmacokinetics. The aim of this work is to ascertain the association between TAC IPV at 6 months after liver transplantation (LT) and patient outcome. This single-center cohort study retrospectively analyzed adult patients who underwent transplantation from 2015 to 2019 who survived the first 6 months with a functioning graft. The primary end point was the patient's probability of death and the secondary outcome was the loss of renal function between month 6 and the last follow-up. TAC IPV was estimated by calculating the coefficient of variation (CV) of the dose-corrected concentration (C₀ /D) between the third and sixth months post-LT. Of the 140 patients who underwe

SUBMITTER: Dopazo C 

PROVIDER: S-EPMC9199878 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature